InvestorsHub Logo
Followers 826
Posts 119434
Boards Moderated 16
Alias Born 09/05/2002

Re: SevenTenEleven post# 158

Tuesday, 11/03/2015 6:36:50 PM

Tuesday, November 03, 2015 6:36:50 PM

Post# of 232
Cleviprex and Cangrelor (without Angiomax) don't amount to much, which is why I think MDCO might still have want to license EGRX's formulation of Angiomax.

It makes no difference to me whether the CV business gets spun out or stays with the parent company. Based on the CC, there are various reorganization options that are being considered.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”